# Junta clínica — PT-pseudo_f80c073525b1 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_f80c073525b1",
  "pid": "PT-pseudo_f80c073525b1",
  "task": 1,
  "psa": 12.0,
  "age": 71,
  "months": 1,
  "pirads": "5",
  "psad": 0.366,
  "psav": 1.69,
  "psap": 10.4,
  "vol": 32.82,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.86149156,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 12 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 33 mL. DRE nodus. csPCa 0.86.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "65 kg",
    "height": "171 cm",
    "bmi": "22.2",
    "bp": "135/71 mmHg",
    "hr": "63 bpm",
    "smoking": "Ex-smoker (20 pack-yr, quit 2015)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent prostatic antigen elevation alongside recent multiparametric imaging review drives the current urological consultation."
    },
    {
      "s": "History",
      "t": "At 71 years of age, the retired shopkeeper first entered clinical evaluation for prostatic antigen elevation in 2022, entering a period of standard observation. Prior biopsy bucket: None. Moderate lower urinary tract complaints surface, yielding an IPSS score of 17 driven by nocturia and a diminished stream; conservative management suffices. Nuptial status is married, yet daily residence is solitary, with an adult son living in close proximity who provides regular oversight. Physical activity remains robust, featuring three weekly runs covering five kilometres each, alongside total alcohol abstinence. Tobacco use ceased in 2015 after a cumulative 20 pack-year exposure. Surgical past includes a childhood appendectomy and a 2018 right knee arthroscopy, both recovered without complication. Recent activities encompass a routine cognitive screening at a memory clinic, a declined invitation to clinical research, and a two-week Portuguese vacation completed without event. Unexplained weight reduction, skeletal discomfort, and haematuria are categorically denied. Comorbid conditions are absent. Active pharmacotherapy is nil."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: moderately enlarged gland harboring a discrete, firm nodule within the left mid-gland sector; mobility: fixed; asymmetry: notable. Abdominal and cardiovascular surveys reveal no abnormalities, characterized by clear lung fields and regular cardiac rhythms. Hemodynamic parameters remain steady. Overall appearance reflects robust wellness, corresponding to an ECOG performance status of 0."
    }
  ],
  "occupation": "retired shopkeeper",
  "marital": "Married",
  "living": "Lives alone; adult son nearby",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Memory clinic — baseline screening"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 17/35 (moderate LUTS)",
  "admin": "Patient declined research participation previously; respect for AS-related trials.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_f80c073525b1
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.366 ng/mL²
  - PSA velocity: 1.69 ng/mL/yr
  - Prior PSA: 10.4 ng/mL
  - Prostate volume: 32.82 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.86149156 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 12 ng/mL. PI-RADS 5. PSAD 0.37. Prostate volume 33 mL. DRE nodus. csPCa 0.86.

Vitals: weight 65 kg, height 171 cm, BMI 22.2, BP 135/71 mmHg, HR 63 bpm. Smoking: Ex-smoker (20 pack-yr, quit 2015).

Chief complaint: Persistent prostatic antigen elevation alongside recent multiparametric imaging review drives the current urological consultation.

History: At 71 years of age, the retired shopkeeper first entered clinical evaluation for prostatic antigen elevation in 2022, entering a period of standard observation. Prior biopsy bucket: None. Moderate lower urinary tract complaints surface, yielding an IPSS score of 17 driven by nocturia and a diminished stream; conservative management suffices. Nuptial status is married, yet daily residence is solitary, with an adult son living in close proximity who provides regular oversight. Physical activity remains robust, featuring three weekly runs covering five kilometres each, alongside total alcohol abstinence. Tobacco use ceased in 2015 after a cumulative 20 pack-year exposure. Surgical past includes a childhood appendectomy and a 2018 right knee arthroscopy, both recovered without complication. Recent activities encompass a routine cognitive screening at a memory clinic, a declined invitation to clinical research, and a two-week Portuguese vacation completed without event. Unexplained weight reduction, skeletal discomfort, and haematuria are categorically denied. Comorbid conditions are absent. Active pharmacotherapy is nil.

Physical examination: DRE — texture: moderately enlarged gland harboring a discrete, firm nodule within the left mid-gland sector; mobility: fixed; asymmetry: notable. Abdominal and cardiovascular surveys reveal no abnormalities, characterized by clear lung fields and regular cardiac rhythms. Hemodynamic parameters remain steady. Overall appearance reflects robust wellness, corresponding to an ECOG performance status of 0.

Patient info: retired shopkeeper; Married; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 17/35 (moderate LUTS).

Recent other appointments: Memory clinic — baseline screening.
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.85
  uncertainty  +/- 0.06 epistemic (95% band 0.74-0.97); among patients I cannot tell apart the outcome was 0.60 of 1.00 mixed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 88% of the time over the 33 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.80: PI-RADS 5, PSA 15.8, PSAD 0.318, age 67, DRE Nodus -> BIOPSY (clear). He wrote: "Younger patient, no reported comorbidity, high elevated PSA, high PSAdensity, PIRADS5, positive DRE. Clear indication biopsy."
  2. distance 1.23: PI-RADS 5, PSA 7.6, PSAD 0.236, age 78, DRE Nodus -> BIOPSY (borderline). He wrote: "This is borderline. A P5 but old man and moderately PSA with no symptoms."
  3. distance 1.57: PI-RADS 5, PSA 12.0, PSAD 0.411, age 71, DRE Normal -> BIOPSY (borderline). He wrote: "P5 in 71 years old patient with no major comorbidities"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 24 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=noted, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines link the PI-RADS score to the indication for biopsy. The guideline states that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. It also notes that MRI-directed US-guided prostate biopsy is now the standard of care.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is based on a broad panel of variables, but the guideline makes the PI-RADS score a decisive factor for triggering the decision. The cohort criterion specifically states that the decision hinges on whether the mpMRI shows a PI-RADS 3 or higher lesion.

WHAT WE STILL NEED
The panel already contains the PI-RADS score of 5, which is above the threshold of 3. The panel also contains the prior-biopsy status, which is "None," which is a factor in the guideline's risk assessment. The panel also contains the DRE finding of "Nodus," which is a factor in the guideline's risk assessment.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly points towards biopsy based on the PI-RADS score and the cohort criterion, but we need to establish the context from the radiology report and previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone described in the mpMRI prose?
  psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  previous_notes (get_previous_notes) -> What is the management context regarding prior biopsy status, surveillance protocol, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the size and zone of the lesion described in the radiology report?
  Q2. What is the management context regarding prior biopsy status, surveillance protocol, and planned treatment detailed in the previous notes?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI Prostate | Date: 15 Jan 2025 | Facility: Amsterdam UMC (VUmc)
What is the lesion size and zone described in the mpMRI prose?
A discrete hypointense focus, roughly 14 x 12 mm, situated within the left mid-gland peripheral zone.

psa_trend
What is the serial PSA trend beyond the headline value?
{"date": "Apr 2022", "val": 3.7}, {"date": "Sep 2023", "val": 6.7}, {"date": "Feb 2025", "val": 12.0}

previous_notes
What is the management context regarding prior biopsy status, surveillance protocol, and planned treatment?
{"date": "06 Jun 2024", "author": "Dr. E. Mulder (GP)", "text": "Tracking data indicates a rise to 10.4 ng/mL relative to the April 2022 baseline. Accompanied by moderate lower urinary complaints, this pattern triggered specialist consultation and advanced imaging. Interim observation proceeds.", "date": "12 Feb 2023", "author": "Dr. E. Mulder (GP)", "text": "April 2022 records document an initial elevation to 9.4 ng/mL. Subsequent checks show stability without acute shifts, while conservative measures address lower urinary tract complaints. Standard surveillance intervals guide ongoing care."}

WHAT I DID NOT OPEN
family-history anamnesis, because it was not requested by the moderator and is not critical to the PI-RADS/biopsy decision based on the opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the left mid-gland peripheral zone (radiology_report)
PI-RADS score of 5 is above the EAU threshold of 3 (EXPERT-EAU)

AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The findings strongly support biopsy due to the PI-RADS 5 score, which is the decisive factor according to the EAU guideline and the cohort criterion. This confirms the Expert-STRUCTURED's suggestion.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 12.00 ng/mL over 3 points spanning 34 months; velocity +2.93 ng/mL per year; doubling time about 20 months.
PROJECTION at 6 months: 19.9 ng/mL, conformal 95% band 5.7-69.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.82
  uncertainty  +/- 0.06 epistemic (95% band 0.70-0.94), of which 0.01 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.85  ('firm' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.82  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)
  EXPERT-COHORT      BIOPSY  (rule pirads_ge_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_ge_3) — carried by EXPERT-COHORT.
PANEL ANSWER: BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=noted, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—the radiology report, PSA trend, and previous notes—directly answer both moderator questions. The report provides the lesion size and zone, and the previous notes detail the management context regarding prior biopsy status and surveillance.

ALIGNMENT WITH THE PANEL
The retrieved evidence strongly aligns with the PANEL-PROTOCOL's answer of BIOPSY, as the PI-RADS 5 score (from the panel) is above the EAU threshold of 3, which is the rule that fired.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the size and zone of the lesion described in the radiology report? Answered by the radiology_report: "A discrete hypointense focus, roughly 14 x 12 mm, situated within the left mid-gland peripheral zone." Q2. What is the management context regarding prior biopsy status, surveillance protocol, and planned treatment detailed in the previous notes? Answered by the previous_notes: The notes detail tracking data, prior elevation to 10.4 ng/mL, and interim observation proceeding.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 5 is the most critical variable because it is the decisive factor according to the EAU guideline and the cohort criterion. The lesion size (14 x 12 mm) and location (left mid-gland peripheral zone) from the radiology report provide crucial anatomical context supporting the high-risk assessment.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with biopsy firmly, as the retrieved evidence confirms the primary guideline-driven indication (PI-RADS $\ge 3$) and the panel's conclusion.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the PI-RADS score of 5, which is above the EAU threshold of 3, is the decisive factor according to the cohort criterion. This finding is strongly supported by the retrieved radiology report detailing a 14 x 12 mm lesion in the left mid-gland peripheral zone. The evidence converged on this decision, as the PI-RADS score was the primary driver, confirming the panel's conclusion.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
